Alnylam Pharmace. buy Truist Financial Co.
Start price
21.07.25
/
50%
€275.00
Target price
21.07.26
€331.29
Performance (%)
0.62%
Price
23.07.25
€276.70
Summary
This prediction is currently active. The BUY prediction by Truist_Financial_Co_ for Alnylam Pharmace. is nearly unchanged. This prediction currently runs until 21.07.26. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | 0.62% |
| iShares Core DAX® | -0.519% |
| iShares Nasdaq 100 | -0.737% |
| iShares Nikkei 225® | 3.828% |
| iShares S&P 500 | -0.355% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $385.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat